SCM
GMAB icon

Suvretta Capital Management’s Genmab GMAB Stock Holding History

Suvretta Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,210
Closed -$221K – 103
2022
Q4 		$221K Buy
+5,210
New +$215K 0.01% 85

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Suvretta Capital Management's GMAB Position: Q1 2023 in Review

Suvretta Capital Management sold out of Genmab (GMAB) in Q1 2023, closing a stake of 5,210 shares — an estimated $221K sold.

Suvretta Capital Management first reported a position in GMAB in Q4 2022 and held it in 1 quarter. The position peaked at $221K in Q4 2022. 216 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

  • Suvretta Capital Management reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
  • Suvretta Capital Management sold 5,210 Genmab shares in Q1 2023, an estimated $221K.
  • Suvretta Capital Management first reported a position in Genmab in Q4 2022 and held it in 1 quarter.
  • Suvretta Capital Management's Genmab position peaked at $221K in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Suvretta Capital Management's 13F filing for Q1 2023, filed 15 May 2023.